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Abstract
Background: Omega-3 and -6 polyunsaturated fatty acids (LCPUFA), are important for good health conditions.
They are present in membrane phospholipids.
The ratio of total n-6:n-3 LCPUFA and arachidonic acid:eicosapentaenoic acid (AA and EPA), should not exceed 5:1.
Increased intake of n-6 and decreased consumption of n-3 has resulted in much higher, ca 10/15:1 ratio in RBC fatty
acids with the possible appearance of a pathological “scenario”. The determination of RBC phospholipid LCPUFA con-
tents and ratios is the method of choice for assessing fatty acid status but it is labour intensive and time consuming.
Aims of the study: [i] To describe and validate a rapid method, suitable for large scale population studies, for total
blood fatty acid assay; [ii] to verify a possible correlation between total n-6:n-3 ratio and AA:EPA ratios in RBC
phospholipids and in whole-blood total lipids, [iii] to assess usefulness of these ratio as biomarkers of LCPUFA status.
Methods: [1] Healthy volunteers and patients with various pathologies were recruited.
[2] Fatty acid analyses by GC of methyl esters from directly derivatized whole blood total lipids and from RBC
phospholipids were performed on fasting blood samples from 1432 subjects categorised according to their age,
sex and any existing pathologies.
AA:EPA ratio and the total n-6:n-3 ratio were determined.
Results: AA:EPA ratio is a more sensitive and reliable index for determining changes in total blood fatty acid and it
is correlated with the ratio derived from extracted RBC phospholipids.
Conclusions: The described AA:EPA ratio is a simple, rapid and reliable method for determining n-3 fatty acid
status.
Background
The evidence that diet is a key component of general
health is well accepted. Governments are developing
health strategies that propose to modify the diet and
lifestyle of their citizens in order to reduce the incidence
of diet-related conditions such as obesity, cardiovascular
disease, cancer, type 2 diabetes and mental health pro-
blems and reduce the health-associated social and
healthcare costs.
Food manufacturers have reacted to the new market
demands for healthier products in two ways. Firstly,
they have attempted to eliminate or reduce “negative”
nutrients, such as trans-fats, saturated fat, sugars with
high glycaemic index and salt, and secondly, they are
adding ingredients to their products with known and
substantiated health benefits. An example of the latter
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long-chain, omega-3 polyunsaturated fatty acids (omega-
3 LCPUFAs), [eicosapentaenoic acid (EPA) and docoso-
hexaenoic acid (DHA)] found naturally in human breast
milk, in marine algae and in the oil of fish such as tuna,
mackerel, herring, salmon and sardines.
Numerous studies have reported a variety of beneficial
effects of omega-3 fatty acids on human health [1].
In humans, EPA (20:5n-3) and DHA (22:6n-3) can be
biosynthesized from the parent essential fatty acid
alpha-linolenic acid (ALA; 18:3n-3). However, due to
low conversion rates of ALA into EPA, and particularly
DHA, the dietary intake of ALA must be relatively high
and the intake of LA, a metabolic competitor for the
biosynthetic pathway, low if this pathway was to meet
the body’sn e e d sf o rt h el o n g e rc h a i nd e r i v a t i v e s .F i s h
do not synthesize the greater proportion of these com-
pounds found in their tissues. They are obtained from
single-cell marine organisms that fish and shellfish regu-
larly consume. EPA and DHA are found mainly in fish
that live in cold, deep seas [2].
The omega-6 PUFAs can be found in vegetable oils,
and they are present in smaller amounts in breast milk.
The parent essential fatty acid of the omega-6 family is
linoleic acid (C18:2n-6, LA). LA, ALA and their meta-
bolic products, arachidonic acid (C20:4n-6, AA) together
with EPA and DHA play a key role as structural and
functional components of cellular and intracellular
membranes throughout the human body, but especially
in brain, heart, retina, and testes.
Many international agencies suggest that LCPUFAs
should provide about 7% of total calories and that the
omega-6/omega-3 ratio should be no more than 5:1 [3].
Recent reports suggest that the total dietary amounts of
these fatty acids are also important and that diets with
similar ratios of n-6:n-3 elicit different metabolic effects
depending on their actual amounts. Increasing absolute
amounts of a-linolenic acid whilst keeping the ratios of
n-6:n-3 the same resulted in a greater conversion of the
precursor fatty acids to EPA and DHA which high-
lighted the competitive interactions of these substrates
for the elongation/desaturation/membrane incorporation
pathways in man. The amounts of other fatty acids in
membrane lipids would reduce the availability of the AA
and EPA after phospholipolysis and would be expected
to alter EFA (Essential Fatty Acids) metabolism. This
does not preclude the usefulness of the AA:EPA ratio in
membrane and whole blood phospholipids as a biomar-
ker for omega-6:omega-3 status in man.
AA is released from phospholipids by phospholipase
A2 and is the precursor of the eicosanoids, which include
prostaglandins of the 2 series (PGE2, PGD2), leukotrienes
of the 4 series (LTA4,L T B 4,L T C 4,L T D 4,L T E 4), and
lipoxines [4]. Their production is catalyzed by
cyclooxygenase, lipooxygenase and epoxygenase enzymes
respectively. These omega-6 derived eicosanoids have
numerous, physiologically important roles including aug-
menting inflammation, modulating immunity and pro-
moting platelet aggregation and vasoconstriction.
The omega-3 EPA can compete with AA for the same
enzymes to form different classes of eicosanoids, namely
3 series PGs and 5 series LTs which can counteract the
deleterious effects of 2-series prostanoids.
Omega-6 and omega-3 fatty acids are both incorpo-
rated into membrane phospholipids when the AA/EPA
ratio is between 1:1 to 5-10:1. When the ratio is higher,
the incorporation of AA is preferred, suggesting a
greater affinity of the enzymes for EPA [5]. The pre-
dicted production of the 2-series eicosanoids therefore
increases, giving rise to pro-inflammatory and pro-
aggregatory conditions.
The omega-3 LCPUFAs present a wide range of bene-
ficial properties. Studies in vitro and with animal models
have indicated that they affect membrane lipid composi-
tion, blood lipid profiles, eicosanoids biosynthesis, cell
signalling cascades, gene expression and the functioning
of the cardiovascular system; they are involved in ameli-
orating or preventing the aetiology of a number of dif-
ferent pathologies [6-9].
It is now recognized that omega-3 LCPUFAs have an
important role in growth and development of the ner-
vous system and retina and are involved in the regula-
tion of cognitive and visual functions and in general
mental health [10-12]. The highest concentrations of
DHA are found in the cerebral cortex, synaptic vesicles
and synaptosomes [13-16]. DHA represents the preva-
lent fatty acid in cerebral gray matter phospholipids,
comprising 45% to 65% of the total fatty acid content in
phosphatidylserine of the CNS [7].
An increasing number of reports demonstrate that
DHA-containing phospholipids can influence membrane
properties such as permeability, fusion, and plane elasti-
city [6].
The effect of omega-3 LCPUFAs on gene expression is
shown by their influence on the plasma triglyceride
(TG) profile. The only fully recognized therapeutic
action of omega-3 is the clinically certified decrease of
plasma TG concentration following their supplementa-
tion [17-19] which is due to the up-regulation of
enzymes involved in fatty acid b-oxidation and down-
regulation of enzymes of fatty acid synthesis [20].
Another positive effect of omega-3 LCPUFAs is the
control of cardiac arrhythmia that is linked to the mod-
ulation of specific calcium ion channels in cardiomo-
cytes [21,22].
Many observational studies (e.g. in cancer and neuro-
degenerative diseases) have postulated the possible thera-
peutic potential of omega-3 LCPUFAs supplementation,
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affected subjects showed a low content of omega-3
LCPUFAs, in particular of EPA [23-28]. However, the
usefulness of the clinico-chemical methods and indices
used to assess the LCPUFA content in the cells and
blood of subjects are labour-intensive and difficult to
compare. Total omega-6 versus total omega-3 fatty acid
ratios in different circulating cells and in blood plasma
has been used, but comparisons with the more specific
AA/EPA ratio are few and show some discrepancies.
The primary aim of this study was to evaluate the AA/
EPA ratio in directly derivatised whole blood as a simple
metabolic index of the LCPUFA status of subjects of dif-
ferent ages, omega-3 intake and pathologies by comparing
it with the total omega-6/omega-3 fatty acid ratios in
whole blood and in RBC membrane phospholipids, which
has historically been the standard for assessing longer-
term intake of the LCPUFA in man. We analysed whole
blood samples from subjects classified by age, sex and
health status, with or without self-motivated omega-3 sup-
plement consumption, using a simple, direct derivatisation
method. RBC cell membranes were isolated, their phos-
pholipids were extracted by standard chromatographic
procedures, their fatty acids derivatised and analysed by
gas chromatography to assess specific n-6:n-3 ratios in cell
membrane phospholipids by the standard method.
Materials and methods
Subjects
Fasted blood samples from 1432 subjects, who were
referred by their physicians, were analysed to assess their
AA/EPA and total n-6:n-3 ratios in whole blood and in
RBC membrane phospholipids. The subjects declared their
age, sex and health status, and willingness to receive an
omega-3 supplement. The dose of the supplement, when
used, was 2-3 g/day of EPA and DHA in a ratio of 2:1.
As reported in Table 1, 300 apparently healthy sub-
jects did not consume omega-3, while 344 consumed
omega-3 regularly. Out of a total of 798 subjects suffer-
ing from various pathological diseases, 577 did not con-
sume any supplement and 211 consumed a supplement
on a regular basis.
To determine any further correlation, the healthy sub-
jects were grouped by age, while pathological subjects
were grouped by declared disease. Numbers in each dis-
ease category and in healthy individual groups are given
in the graphs.
Methods
Blood (2 ml) was drawn from an antecubital vein and
maintained at 2-4°C for no more than 24 hours from
the time of sampling to methylester preparation.
An aliquot of whole blood was derivatised directly, as
described below, for GC analysis of the fatty acid
composition.
Erythrocytes (RBC) were separated by centrifugation
(2000 rpm for 10 minutes, ALC 4232 centrifuge) and
stored at -70°C in isotonic buffer until used for mem-
brane purification.
Cell membranes of RBC (ghosts) were prepared by
lysis with hypotonic buffer (phosphate 5 mM, pH 8,
EDTA 0.5 mM), precipitated by centrifugation and
washed several times to eliminate haemoglobin residues.
Ghost lipids were extracted with chloroform/methanol
according to Folch [29], and fractionated by silicic acid
chromatography (200-400 mesh BIORAD, CA) into
non-polar lipids, glycolipids and phospholipids [30].
Table 1 The fatty acid profiles (% composition) of whole blood lipids in subjects from an Italian population not
consuming omega-3 supplements and arranged according to age
% Under 20
years (15-20)
21-40
years
41-60
years
Over 60
years (61-81)
n 19 103 127 51
Mean S.E. Mean S.E. Mean S.E. Mean S.E.
C16:0 * 21.634 0.535 22.226 0.295 22.779 0.194 23.441 0.343
C16:1** 1.252 0.228 1.392 0.066 1.438 0.064 1.945 0.140
C18:0 12.321 0.547 11.197 0.259 11.364 0.170 10.836 0.251
C18:1** 22.154 0.823 23.959 0.385 23.537 0.330 25.728 0.600
C18:2n-6** (LA) 23.089 0.735 22.155 0.347 21.795 0.371 19.527 0.463
C18:3n-3 (ALA) 0.431 0.036 0.451 0.028 0.450 0.023 0.477 0.030
C20:3n-6 2.098 0.117 1.932 0.056 1.860 0.060 2.174 0.289
C20:4n-6*(AA) 12.145 0.454 11.412 0.200 11.064 0.171 10.690 0.280
C20:5 n-3 (EPA) 0.670 0.093 1.022 0.111 1.132 0.077 1.040 0.090
C22:5n-3 (DPA) 1.381 0.106 1.264 0.048 1.266 0.044 1.203 0.060
C22:6n-3 (DHA) 2.825 0.293 2.989 0.100 3.315 0.115 2.940 0.150
tot ω-6** 37.332 0.845 35.499 0.403 34.719 0.381 32.391 0.624
tot ω-3 5.307 0.394 5.727 0.197 6.163 0.198 5.659 0.240
a) Overall significance by ANOVA: * p < 0.05; ** p < 0.01.
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The fatty acid composition of whole blood and of RBC
membrane phospholipids was determined as follows.
RBC membrane phospholipids were isolated, extracted
and separated by standard procedures prior to derivati-
sation to their component fatty acid methyl esters
(FAME) by sodium methoxide. FAME of whole blood
were obtained by direct derivatization of an aliquot of
freshly drawn blood with sodium methoxide in metha-
nol 3.33% (w/v). FAME were rapidly extracted into
petroleum ether/diethyl ether and rapidly dried. They
were then injected into a gas chromatograph (Agilent
Technologies 6850 series II, CA) equipped with flame
ionization detector. (Capillary column, AT Silar length
30 m, film thickness 0.25 μm; carrier gas, helium;
injector temperature, 250°C; detector temperature, 275°
C). The oven temperature was controlled at 50°C for 2
min and then increased at a rate of 10°C min
-1 to 200°
C, and maintained there for 20 min. A standard mix-
ture containing all fatty acid methylesters (Sigma-
Aldrich, MO) was injected for calibration each day
[31].
Total omega-6/omega-3 fatty acids and the AA/EPA
ratios were calculated for whole blood and for RBC
membrane phospholipids.
Statistical analysis
Results were expressed as mean ± SEM; all the data
were analyzed by analysis of variance (ANOVA). Stu-
dent’s t-test was used for comparisons between two
groups.
Results
A comparison between the total omega-6:omega-3 ratios
in directly derivatised whole blood and those in isolated
RBC membrane phospholipids from 150 patients
showed a good correlation (R
2 = 0.711) (Figure 1a).
However, the comparison of the more specific AA/EPA
ratios in whole blood and in RBC membrane phospholi-
pids showed a much stronger correlation (R
2 = 0.868)
(Figure 1b).
Healthy subjects, that did not take any fish oil supple-
ments, were divided into four groups according to age:
[i] under 20 years, [ii] 21-40 years, [iii] 41-60 years, and
[iv] over 60 years. The fatty acid profiles (%
Figure 1 Comparison of the linear correlations between the total omega-6/omega-3 ratios (A) and the AA/EPA ratios (B) in whole
blood and in RBC membrane.
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groups are reported in Table 1. Many differences in
fatty acid proportions become apparent, such as a
decrease of palmitic acid with an increase of palmitoleic
and oleic acids, with increasing age of the subjects. No
difference were related to sex (data not shown).
Figure 2 depicts the AA/EPA ratios and total omega-
6/omega-3 ratios in the whole blood of the four groups
of healthy subjects who did not consume omega-3 sup-
plements and were classified by age as in Table 1. There
was an overall decrease of the AA/EPA ratio with aging,
with statistical significance observed only for subjects
older than 40 years.
This difference resulted from a slight increase of EPA
with a significant decrease of AA (Table 1). Also, there
was a slight increase in DHA content from under 20
years up to 60 years of age but a marked decrease for
subjects over 60 years old. Smaller differences were
observed in the total omega-6/omega-3 ratio, related to
age, even when there was a significant decrease of total
omega-6 fatty acids (Table 1).
The total omega-6/omega-3 and AA:EPA ratios in
the whole blood of healthy subjects and in patients
with various diseases, with or without omega-3 supple-
mentation, are compared in Figure 3. The AA:EPA
ratio in healthy subjects who did not consume omega-
3 supplements was high relative to values recom-
mended by nutritional guidelines. In healthy subjects
consuming omega-3, the ratio, as expected, was signifi-
cantly lower, but with values in a range that is consid-
ered to be safe.
Patients suffering from various diseases, irrespective of
the type of pathology and the consumption of omega-3,
had higher AA:EPA ratios than healthy subjects
suggesting a decreased omega-3 intake or increased turn-
over, or an increased omega-6 intake, or decreased turn-
over. Nevertheless, in both patients with disease and in
healthy subjects, the voluntary consumption of an
omega-3 supplement (2-3 g of EPA/DHA) resulted in a
statistically significant decrease of the AA:EPA ratio indi-
cating that the methodology was very sensitive to such
changes in fatty acid intake. The total omega-6:omega-3
ratio was also higher in subjects with disease compared
to healthy subjects, although the differences were less
marked compared to those of the AA:EPA ratio.
AA:EPA and total omega-6:omega-3 ratios in directly
derivatised whole blood from patients with different
pathologies are shown in Figure 4A and 4B, respectively.
The number of subjects in each disease category is
shown on the graph. The upper horizontal lines indicate
the mean values found in healthy subjects not taking
omega-3 supplements. Subjects that did not take
omega-3 supplements and suffered from allergic, neuro-
degenerative, skin and inflammatory diseases had higher
values for AA:EPA ratios than those with the other dis-
eases (heart, metabolic, cancer). Ratios in all the pathol-
ogies were, however, reduced in patients that used an
omega-3 supplement, albeit to slightly different degrees.
From the data in Figure 4B, less marked differences
were observed for each disease when the total omega-6:
omega-3 ratio of membrane/blood lipids was
determined.
Discussion
The essential LCPUFAs play important and positive
roles in maintaining normal physiological conditions
and consequently health in humans. Some chronic
pathologies are associated with defective metabolism of
Figure 2 The AA/EPA and total omega-6/omega-3 ratios in whole blood of healthy subjects not using fish oil supplements and
grouped by age. Mean ± S.E; Student’s t-test: * p < 0.05 vs 0-20; § p < 0.05 vs 21-40; §§ p < 0.01 vs 21-40, number of subjects as in table 1.
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pathologies, with and without consumption of omega-3. Mean ± S.E; Student’s t-test: ## p < 0.01 with omega-3 vs without omega-3; ** p <
0.01 pathological vs healthy; number of subjects as in Table 1.
Figure 4 (A) AA/EPA ratios and (B) omega-6/omega-3 ratios in whole blood of patients grouped according to their specific
pathologies. The horizontal lines indicate the mean value for all the healthy subjects that do not use omega-3.
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arachidonic acids and the omega-3 eicosapentaenoic
(EPA) and docosahexaenoic (DHA) LCPUFAs.
Analysis of the composition of these fatty acids in
phospholipids of RBC membranes provides information
about their longer-term (approximately 125 days, RBC
lifespan) dietary intake and their biosynthetic conversion
to eicosanoids and certain metabolic anomalies (e.g.
delta 6-desaturase deficiency). In clinical practice, deter-
mination of RBC membrane phospholipid fatty acid
composition is a standard diagnostic procedure for eval-
uating essential fatty acid status and for use as a bio-
marker for different pathologies [32,33], particularly
concerning cardiovascular diseases [34-36]. However,
assessing this biomarker requires a lengthy, labour
intensive, multi-step analytical procedure.
We have tested a rapid, simple and reliable method to
determine AA:EPA and total omega-6:omega-3 ratios in
whole blood lipids against the standard RBC membrane
phospholipid composition method. The AA:EPA ratios
in the directly derived whole blood lipids were very clo-
sely correlated with those obtained by the standard
method from RBC membrane phospholipids in a large
population group. The more specific AA:EPA ratios also
showed better correlations than the total omega-6:
omega-3 ratios using both whole blood and membrane
methods (R
2 = 0.868 vs 0.711 respectively). This sug-
gested that the former was the more sensitive ratio to
use. The method was validated in healthy subjects of
varying ages and in patients with various pathologies. A
statistically significant decrease of the AA:EPA ratio was
observed in subjects over 40 years old, which resulted
from a simultaneous increase of EPA and a decrease of
AA, irrespective of gender. Less significant differences
were observed for the total omega-6:omega-3 ratio, even
when the total content of omega-6 was decreased signif-
icantly. Previous studies on a Canadian population
showed a higher level of omega-3 only in elderly sub-
jects [37], probably due to an increased consumption of
seafood, although a decreased oxidation of omega-3 in
elderly compared to younger volunteers may also play a
role [38]. As a working hypothesis and according to
observations on prostaglandin synthesis [39], we suggest
that the lower level of circulating AA may also be attrib-
uted, at least in part, to a reduction of Δ6d e s a t u r a s e
activity in elderly subjects. However, these observations
need to be confirmed by larger studies.
The AA:EPA ratio in healthy Italian subjects without
supplementation is high in the present study and is
comparable to that reported for other Western popula-
tions where the ratio of omega-6 to omega-3 fatty acids
in the diet is also high [40,41]. In subjects using an
omega-3 supplement, the ratios were significantly
decreased but the values were considered to be safe and
more beneficial to health [9].
Patients with allergic, skin and neurodegenerative dis-
eases had higher ratios of AA:EPA compared to the
values for subjects with other pathologies. The reasons
for this are not immediately apparent but could reflect
differences in intake and/or metabolism, particularly an
increased turnover of EPA. More work is required with
individuals presenting with different pathologies and
consuming varying levels of omega-3 before the
observed ratios can be considered as actual biomarkers
for specific diseases.
Similar results to those with the AA:EPA ratios were
obtained for the total omega-6:omega-3 ratios in both
whole blood and RBC membrane phospholipids,
although in most cases the differences were much smal-
ler, probably due to the diet of the subjects that may
include varying amounts of omega-6 fatty acids, particu-
larly linoleic acid from vegetable oils.
In conclusion, our observations show that a simple,
direct derivatisation method of assessing fatty acid pro-
files in whole blood is a rapid, reliable and reproducible
tool for determining the fatty acid status of subjects of
different ages and pathologies. The simplicity of the
method makes it particularly useful for assessing the
fatty acid status of large cohorts where the use of RBC
membrane phospholipids would be a daunting prospect.
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